Signaling molecules and pathways involved in MSC tumor tropism

Histology and Histopathology

Volumn 28, Issue 11, 2013, Pages 1427-1438

  Ho, Ivy Aw ^a   Lam, Paula Y P ^a,b,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Mesenchymal stem cells; Migration; Tumor tropism

Indexed keywords

ANIMAL; CELL MOTION; CYTOLOGY; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL MOVEMENT; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84886302561     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Amersi F.F., Terando A.M., Goto Y., Scolyer R.A., Thompson J.F., Tran A.N., Faries M.B., Morton D.L. and Hoon D.S. (2008). Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin. Cancer Res. 14, 638-645.
2. Ball S.G., Bayley C., Shuttleworth C.A. and Kielty C.M. (2010a). Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells. Biochem. J. 427, 29-40.
3. Ball S.G., Shuttleworth C.A. and Kielty C.M. (2010b). Platelet-derived growth factor receptors regulate mesenchymal stem cell fate: implications for neovascularization. Expert Opin. Biol. Ther. 10, 57-71.
4. Barrilleaux B.L., Fischer-Valuck B.W., Gilliam J.K., Phinney D.G. and O'Connor K.C. (2010). Activation of CD74 inhibits migration of human mesenchymal stem cells. In Vitro Cell Dev. Biol. Anim. 46, 566-572.
5. Barry F.P., Murphy J.M., English K. and Mahon B.P. (2005). Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev. 14, 252-265.
6. Beckermann B.M., Kallifatidis G., Groth A., Frommhold D., Apel A., Mattern J., Salnikov A.V., Moldenhauer G., Wagner W., Diehlmann A., Saffrich R., Schubert M., Ho A.D., Giese N., Buchler, M.W., Friess H., Buchler P. and Herr I. (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 99, 622-631.
7. Behfar A., Yamada, S., Crespo-Diaz R., Nesbitt J.J., Rowe L.A., Perez-Terzic C., Gaussin V., Homsy C., Bartunek J. and Terzic A. (2010). Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol. 56, 721-734.
8. Belema-Bedada F., Uchida S., Martire A., Kostin S. and Braun T. (2008). Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell. 2, 566-575.
9. Bhanot Y., Rao S., Ghosh D., Balaraju S., Radhika C.R. and Satish Kumar, K. V. (2011). Autologous mesenchymal stem cells in chronic spinal cord injury. Br. J. Neurosurg. 25, 516-522.
10. Binger T., Stich S., Andreas K., Kaps C., Sezer O., Notter M., Sittinger M. and Ringe J. (2009). Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25. Exp. Cell Res. 315, 1468-1479.
11. Bos R., van Diest P.J., de Jong J.S., van der Groep P., van der Valk P. and van der Wall E. (2005). Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46, 31-36.
12. Brooke G., Tong H., Levesque J.P. and Atkinson K. (2008). Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev. 17, 929-940.
13. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., Liles W.C., Li X., Graham-Evans B., Campbell T.B., Calandra G., Bridger G., Dale D.C. and Srour E.F. (2005). Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp.Med. 201, 1307-1318.
14. Chakraborti S., Mandal M., Das S., Mandal A. and Chakraborti T. (2003). Regulation of matrix metalloproteinases: an overview. Mol. Cell Biochem. 253, 269-285.
15. Chamberlain G., Wright K., Rot A., Ashton B. and Middleton J. (2008). Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS One 3, e2934.
16. Ciccocioppo R., Bernardo M.E., Sgarella A., Maccario R., Avanzini M.A., Ubezio C., Minelli A., Alvisi C., Vanoli A., Calliada F., Dionigi P., Perotti C., Locatelli F. and Corazza G.R. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60, 788-798.
17. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L. and Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949.
18. Dar A., Kollet O. and Lapidot T. (2006). Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp. Hematol. 34, 967-975.
19. Darash-Yahana M., Gillespie J.W., Hewitt S.M., Chen Y.Y., Maeda S., Stein I., Singh S.P., Bedolla R.B., Peled A., Troyer D.A., Pikarsky E., Karin M. and Farber J.M. (2009). The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4, e6695.
20. Djouad F., Delorme B., Maurice M., Bony C., Apparailly F., Louis-Plence P., Canovas F., Charbord P., Noel D. and Jorgensen C. (2007). Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Res. Ther. 9, R33.
21. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D. and Horwitz E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
22. Duijvestein M., Vos A.C., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., Kooy-Winkelaar E.M., Koning F., Zwaginga J.J., Fidder H.H., Verhaar A.P., Fibbe W.E., van den Brink G.R. and Hommes, D.W. (2010). Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59, 1662-1669.
23. Dwyer R.M., Potter-Beirne S.M., Harrington K.A., Lowery A.J., Hennessy E., Murphy J.M., Barry F.P., O'Brien T. and Kerin M.J. (2007). Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res. 13, 5020-5027.
24. Egea, V., von Baumgarten L., Schichor C., Berninger B., Popp T., Neth P., Goldbrunner R., Kienast Y., Winkler F., Jochum M. and Ries, C. (2011). TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma. Cell Death Differ. 18, 853-863.
25. Fiedler J., Etzel N. and Brenner R. (2004). To go or not to go: Migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF. J. Cell. Biochem. 93, 990-998.
26. Fiedler J., Leucht F., Waltenberger J., Dehio C. and Brenner R.E. (2005). VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochem. Biophys. Res. Commun. 334, 561-568.
27. Fierro F.A., Kalomoiris S., Sondergaard C.S. and Nolta J.A. (2011). Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 29, 1727-1737.
28. Fischer-Valuck B.W., Barrilleaux B.L., Phinney D.G., Russell K.C., Prockop D.J. and O'Connor K.C. (2010). Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnol. Lett. 32, 19-27.
29. Francois S., Bensidhoum M., Mouiseddine M., Mazurier C., Allenet B., Semont A., Frick J., Sache A., Bouchet S., Thierry D., Gourmelon P., Gorin N.C. and Chapel A. (2006). Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 24, 1020-1029.
30. Freyman T., Polin G., Osman H., Crary J., Lu M., Cheng L., Palasis M. and Wilensky R.L. (2006). A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur. Heart J. 27, 1114-1122.
31. Fu X., Han B., Cai S., Lei Y., Sun T. and Sheng Z. (2009). Migration of bone marrow-derived mesenchymal stem cells induced by tumor necrosis factor-alpha and its possible role in wound healing. Wound Repair Regen. 17, 185-191.
32. Ghosh M.C., Makena P.S., Gorantla V., Sinclair S.E. and Waters C.M. (2012). CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2. Am. J. Physiol. Lung Cell Mol. Physiol. 302, L846-856.
33. Gondi C.S., Veeravalli K.K., Gorantla B., Dinh D.H., Fassett D., Klopfenstein J.D., Gujrati M. and Rao J. S. (2010). Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. Neuro Oncol. 12, 453-465.
34. Granero-Molto F., Weis J.A., Miga M.I., Landis B., Myers T.J., O'Rear L., Longobardi L., Jansen E.D., Mortlock D.P. and Spagnoli A. (2009). Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 27, 1887-1898.
35. Gutova M., Najbauer J., Frank R.T., Kendall S.E., Gevorgyan A., Metz M.Z., Guevorkian M., Edmiston, M., Zhao D., Glackin C.A., Kim S.U. and Aboody K.S. (2008). uPA and uPAR mediate human stem cell tropism to malignant solid tumors. Stem Cells 26, 1406-1413.
36. Halpern J.L., Kilbarger A. and Lynch C.C. (2011). Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 308, 91-99.
37. Hata N., Shinojima N., Gumin J., Yong R., Marini F., Andreeff M. and Lang F.F. (2010). Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 66, 144-156; discussion 156-147.
38. Hess D.A. and Allan A.L. (2011). Migratory strategies of normal and malignant stem cells. Methods Mol. Biol. 750, 25-44.
39. Ho I.A., Chan K.Y., Ng W.H., Guo C.M., Hui K.M., Cheang P. and Lam P.Y. (2009). Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27, 1366-1375.
40. Honczarenko M., Le Y., Swierkowski M., Ghiran I., Glodek A.M. and Silberstein L. (2006). Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24, 1030-1041.
41. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M. and Feng Z.H. (2007). CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 252, 86-92.
42. Huang W., Zhang D., Millard R.W., Wang T., Zhao T., Fan G.C., Ashraf A., Xu M., Ashraf M. and Wang Y. (2010). Gene manipulated peritoneal cell patch repairs infarcted myocardium. J Mol. Cell Cardiol. 48, 702-712.
43. Huang W., Wang T., Zhang D., Zhao T., Dai B., Ashraf A., Wang X., Xu M., Millard R.W., Fan G.C., Ashraf M., Yu X.Y. and Wang Y. (2012). Mesenchymal stem cells overexpressing CXCR4 attenuate remodeling of postmyocardial infarction by releasing matrix metalloproteinase-9. Stem Cells Dev. 21, 778-789.
44. Ip J.E., Wu Y., Huang J., Zhang L., Pratt R.E. and Dzau V.J. (2007). Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol. Biol. Cell. 18, 2873-2882.
45. Jacobs J.F., Idema A.J., Bol K.F., Grotenhuis J.A., de Vries I.J., Wesseling P. and Adema G.J. (2010). Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol. 225, 195-199.
46. Johnson E.L., Singh R., Singh S., Johnson-Holiday C.M., Grizzle W.E., Partridge E.E. and Lillard J.W. Jr (2010). CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J. Surg. Oncol. 8, 62.
47. Johnson-Holiday C., Singh R., Johnson E., Singh S., Stockard C.R., Grizzle W.E. and Lillard J.W. Jr (2011). CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int. J. Oncol. 38, 1279-1285.
48. Jorgensen E., Baldazzi F., Ripa R.S., Friis T., Wang Y., Helqvist S. and Kastrup J. (2010). Instent neointimal hyperplasia after percutaneous intervention for ST-elevation myocardial infarction and treatment with granulocyte-colony stimulating factor. Results from the stem cells in myocardial infarction (STEMMI) trial. Int. J. Cardiol. 139, 269-275.
49. Katou F., Ohtani H., Nakayama T., Ono K., Matsushima K., Saaristo A., Nagura H., Yoshie O. and Motegi K. (2001). Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am. J. Pathol. 158, 1263-1270.
50. Kidd S., Caldwell L., Dietrich M., Samudio I., Spaeth E.L., Watson K., Shi Y., Abbruzzese J., Konopleva, M., Andreeff M. and Marini F.C. (2010). Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12, 615-625.
51. Kim K.N., Oh S.H., Lee K.H. and Yoon D.H. (2006). Effect of human mesenchymal stem cell transplantation combined with growth factor infusion in the repair of injured spinal cord. Acta Neurochir. (Suppl. 99), 133-136.
52. Kim D.S., Kim J.H., Lee J.K., Choi S.J., Kim J.S., Jeun S.S., Oh W., Yang Y.S. and Chang J.W. (2009). Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev. 18, 511-519.
53. Kim S.M., Oh J.H., Park S.A., Ryu C.H., Lim J.Y., Kim D.S., Chang J.W., Oh W. and Jeun S.S. (2010). Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 28, 2217-2228.
54. Kim S.M., Kim D.S., Jeong C.H., Kim D.H., Kim J.H., Jeon H.B., Kwon S.J., Jeun S.S., Yang Y.S., Oh W. and Chang J.W. (2011). CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem. Biophys. Res. Commun. 407, 741-746.
55. Klopp A.H., Spaeth E.L., Dembinski J.L., Woodward W.A., Munshi A., Meyn R.E., Cox J.D., Andreeff M. and Marini F.C. (2007). Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 67, 11687-11695.
56. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I. and Lazarus H.M. (2000). Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18, 307-316.
57. Kubo M., Li T.S., Kamota T., Ohshima M., Qin S.L. and Hamano K. (2009). Increased expression of CXCR4 and integrin alphaM in hypoxia-preconditioned cells contributes to improved cell retention and angiogenic potency. J. Cell Physiol. 220, 508-514.
58. Langer H.F., Stellos K., Steingen C., Froihofer A., Schonberger T., Kramer B., Bigalke B., May A.E., Seizer P., Muller I., Gieseke F., Siegel-Axel D., Meuth S.G., Schmidt A., Wendel H.P., Muller I., Bloch W. and Gawaz M. (2009). Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. J. Mol. Cell Cardiol. 47, 315-325.
59. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe, W. and Ringden, O. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586.
60. Lee R.H., Seo M.J., Reger R.L., Spees J.L., Pulin A.A., Olson S.D. and Prockop D.J. (2006). Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl. Acad. Sci. USA 103, 17438-17443.
61. Lee M.J., Kim J., Kim M.Y., Bae Y.S., Ryu S.H., Lee T.G. and Kim J. H. (2010). Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J. Proteome Res. 9, 1754-1762.
62. Ley K., Laudanna C., Cybulsky M.I. and Nourshargh S. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689.
63. Li J.M., Zhu H., Lu S., Liu Y., Li Q., Ravenscroft P., Xu Y.F., Huang L., Ma C.M., Bezard E., Zhao R.C., Wang R.Z. and Qin C. (2011). Migration and differentiation of human mesenchymal stem cells in the normal rat brain. Neurol. Res. 33, 84-92.
64. Lim J.Y., Jeong C.H., Jun J.A., Kim S.M., Ryu C.H., Hou Y., Oh W., Chang J.W. and Jeun S.S. (2011). Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Res. Ther. 2, 38.
65. Liu L., Yu Q., Lin J., Lai X., Cao W., Du K., Wang Y., Wu K., Hu Y., Zhang L., Xiao H., Duan Y. and Huang H. (2011). Hypoxia-inducible factor-1alpha is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev. 20, 1961-1971.
66. Lu Y., Cai Z., Galson D.L., Xiao, G. Liu Y., George D.E., Melhem M.F., Yao Z. and Zhang J. (2006). Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66, 1311-1318.
67. Maijenburg M.W., Noort W.A., Kleijer M., Kompier C.J., Weijer K., van Buul J.D., van der Schoot C.E. and Voermans C. (2010). Cell cycle and tissue of origin contribute to the migratory behaviour of human fetal and adult mesenchymal stromal cells. Br. J. Haematol. 148, 428-440.
68. Meng E., Guo Z., Wang H., Jin J., Wang J., Wang H., Wu C. and Wang L. (2008). High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev. 17, 805-813.
69. Mi Z., Bhattacharya S.D., Kim V.M., Guo H., Talbot L.J. and Kuo P.C. (2011). Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32, 477-487.
70. Molloy A.P., Martin F.T., Dwyer R.M., Griffin T.P., Murphy M., Barry F.P., O'Brien T. and Kerin M.J. (2009). Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int. J. Cancer 124, 326-332.
71. Morishita R., Nakamura S., Hayashi S., Aoki M., Matsushita H., Tomita N., Yamamoto K., Moriguchi, A., Higaki J. and Ogihara T. (1998). Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease. J. Atheroscler. Thromb. 4, 128-134.
72. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., Chen J., Hentschel S., Vecil G., Dembinski J., Andreeff M. and Lang F.F. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65, 3307-3318.
73. Neuss S., Becher, E., Woltje M., Tietze L. and Jahnen-Dechent, W. (2004). Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22, 405-414.
74. Newman J.P., Toh X.Y., Chan J., Endaya B. and Lam P. (2011). Migration of human fetal bone marrow-derived mesenchymal stem cells: Possible involvement of GPCR and MMPs. J. Stem Cell Res. Ther. 2011, (special issue):5.
75. Papadakis K.A., Prehn J., Moreno S.T., Cheng L., Kouroumalis E.A., Deem R., Breaverman T., Ponath P.D., Andrew D.P., Green P.H., Hodge M.R., Binder S.W. and Targan S.R. (2001). CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology. 121, 246-254.
76. Park S.A., Ryu C.H., Kim S.M., Lim J.Y., Park S.I., Jeong C.H., Jun J.A., Oh J.H., Park S.H., Oh W. and Jeun S.S. (2011). CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int. J. Oncol. 38, 97-103.
77. Park J.H., Kim D.Y., Sung I.Y., Choi G.H., Jeon M.H., Kim K.K. and Jeon S.R. (2012). Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery 70, 1238-1247; discussion 1247.
78. Peled A., Petit I., Kollet, O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D. and Lapidot T. (1999). Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848.
79. Pevsner-Fischer M., Morad V., Cohen-Sfady M., Rousso-Noori L., Zanin-Zhorov A., Cohen S., Cohen I.R. and Zipori D. (2007). Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109, 1422-1432.
80. Pitchford S.C. and Rankin S.M. (2012). Combinatorial stem cell mobilization in animal models. Methods Mol. Biol. 904, 139-154.
81. Pitchford S.C., Furze R.C., Jones C.P., Wengner A.M. and Rankin S.M. (2009). Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4, 62-72.
82. Prasad V.K., Lucas K.G., Kleiner G.I., Talano J.A., Jacobsohn D., Broadwater G., Monroy R. and Kurtzberg J. (2011). Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol. Blood Marrow Transplant. 17, 534-541.
83. Qi Y., Feng G. and Yan W. (2012). Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol. Biol. Rep. 39, 5683-5689.
84. Rattigan Y., Hsu J.M., Mishra P.J., Glod J. and Banerjee D. (2010). Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp. Cell Res. 316, 3417-3424.
85. Ravanti L. and Kahari V.M. (2000). Matrix metalloproteinases in wound repair (review). Int. J. Mol. Med. 6, 391-407.
86. Ries C., Egea V., Karow M., Kolb H., Jochum M. and Neth P. (2007). MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109, 4055-4063.
87. Ritter E., Perry A., Yu J., Wang T., Tang L. and Bieberich E. (2008). Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann. Surg. 247, 310-314.
88. Rosova I., Dao M., Capoccia B., Link D. and Nolta J. A. (2008). Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26, 2173-2182.
89. Ryu C.H., Park S.A., Kim S.M., Lim J.Y., Jeong C.H., Jun J.A., Oh J.H., Park S.H., Oh W.I. and Jeun S.S. (2010). Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem. Biophys. Res. Commun. 398, 105-110.
90. Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K. and Toi M. (2001). Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92, 1085-1091.
91. Sanchez-Nino M.D., Sanz A.B., Ruiz-Andres O., Poveda, J., Izquierdo M.C., Selgas R., Egido J. and Ortiz A. (2013). MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple. Cytokine Growth Factor Rev. 24, 23-40.
92. Sasaki M., Abe R., Fujita Y., Ando S., Inokuma D. and Shimizu H. (2008). Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 180, 2581-2587.
93. Sato K., Ozaki K., Mori M., Muroi K. and Ozawa K. (2010). Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J. Clin. Exp. Hematop. 50, 79-89.
94. Schichor C., Birnbaum T., Etminan N., Schnell O., Grau S., Miebach S., Aboody K., Padovan C., Straube, A., Tonn J.C. and Goldbrunner R. (2006). Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp. Neurol. 199, 301-310.
95. Schiraldi M., Raucci A., Munoz L.M., Livoti E., Celona B., Venereau E., Apuzzo T., De Marchis F., Pedotti M., Bachi A., Thelen M., Varani L., Mellado M., Proudfoot A., Bianchi M.E. and Uguccioni, M. (2012). HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209, 551-563.
96. Segers V.F., Van Riet I., Andries L.J., Lemmens K., Demolder M.J., De Becker A.J., Kockx M.M. and De Keulenaer G.W. (2006). Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am. J. Physiol. Heart Circ. Physiol. 290, H1370-1377.
97. Shabbir A., Zisa D., Suzuki G. and Lee T. (2009). Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am. J. Physiol. Heart Circ. Physiol. 296, H1888-1897.
98. Shi Y., Xia Y.Y., Wang L., Liu R., Khoo K.S. and Feng Z.W. (2012). Neural cell adhesion molecule modulates mesenchymal stromal cell migration via activation of MAPK/ERK signaling. Exp. Cell Res. 318, 2257-2267.
99. Shinojima N., Hossain A., Takezaki T., Fueyo-Margareto J., Gumin J., Gao F., Nwajei F., Marini F.C., Andreeff M., Kuratsu J.I. and Lang F.F. (2013). TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res. 73, 2333-2344.
100. Singh S., Singh U.P., Stiles J.K., Grizzle W.E. and Lillard J.W. Jr (2004). Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin. Cancer Res. 10, 8743-8750.
101. Smith H., Whittall C., Weksler B. and Middleton J. (2012). Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev. 21, 476-486.
102. Son B.R., Marquez-Curtis L.A., Kucia M., Wysoczynski M., Turner A.R., Ratajczak J., Ratajczak M.Z. and Janowska-Wieczorek A. (2006). Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24, 1254-1264.
103. Song C. and Li G. (2011). CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy 13, 549-561.
104. Song J.S., Kang C.M., Kang H.H., Yoon H.K., Kim Y.K., Kim K.H., Moon H.S. and Park S.H. (2010). Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp. Mol. Med. 42, 465-472.
105. Stich S., Loch A., Leinhase I., Neumann K., Kaps C., Sittinger M. and Ringe J. (2008). Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. Eur. J. Cell Biol. 87, 365-376.
106. Strieter R.M., Standiford T.J., Huffnagle G.B., Colletti L.M., Lukacs N.W. and Kunkel S.L. (1996). The good, the bad, and the ugly. The role of chemokines in models of human disease. J. Immunol. 156, 3583-3586.
107. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J. and Andreeff M. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62, 3603-3608.
108. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., Champlin R.E. and Andreeff M. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96, 1593-1603.
109. Sun X., Wei L., Chen Q. and Terek R.M. (2010). CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol. Cancer. 9, 17.
110. Tamai K., Yamazaki T., Chino T., Ishii M., Otsuru S., Kikuchi Y., Iinuma S., Saga K., Nimura K., Shimbo T., Umegaki N., Katayama I., Miyazaki J., Takeda J., McGrath J.A., Uitto J. and Kaneda, Y. (2011). PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc. Natl. Acad. Sci. USA 108, 6609-6614.
111. Teo G.S., Ankrum J.A., Martinelli R., Boetto S.E., Simms K., Sciuto T.E., Dvorak A.M., Karp J.M. and Carman C.V. (2012). Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 30, 2472-2486.
112. Trachtenberg B., Velazquez D.L., Williams A.R., McNiece I., Fishman J., Nguyen K., Rouy D., Altman P., Schwarz R., Mendizabal A., Oskouei B., Byrnes J., Soto V., Tracy M., Zambrano J.P., Heldman A.W. and Hare J.M. (2011). Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in Chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am. Heart J. 161, 487-493.
113. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H. and Matsushima K. (2000). Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289.
114. Veevers-Lowe J., Ball S.G., Shuttleworth A. and Kielty C.M. (2011). Mesenchymal stem cell migration is regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-beta and potentiation of growth factor signals. J. Cell Sci. 124, 1288-1300.
115. Verma P.K., Bala M., Kumar N. and Singh B. (2012). Therapeutic potential of natural products from terrestrial plants as TNF-alpha antagonist. Curr. Top Med. Chem. 12, 1422-1435.
116. Vogel S., Peters C., Etminan N., Borger V., Schimanski A., Sabel M.C. and Sorg R.V. (2013). Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment. Biochem. Biophys. Res. Commun. 431, 428-432.
117. Walter M.N., Wright K.T., Fuller H.R., MacNeil S. and Johnson W.E. (2010). Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Exp. Cell Res. 316, 1271-1281.
118. Wang L., Li Y., Chen J., Gautam S.C., Zhang Z., Lu M. and Chopp M. (2002a). Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp. Hematol. 30, 831-836.
119. Wang L., Li Y., Chen X., Chen J., Gautam S.C., Xu Y. and Chopp M. (2002b). MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology 7, 113-117.
120. Waterman R.S., Tomchuck S.L., Henkle S.L. and Betancourt A.M. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 5, e10088.
121. Wislet-Gendebien S., Wautier F., Leprince P. and Rogister B. (2005). Astrocytic and neuronal fate of mesenchymal stem cells expressing nestin. Brain Res. Bull. 68, 95-102.
122. Woodfin A., Voisin M.B. and Nourshargh S. (2010). Recent developments and complexities in neutrophil transmigration. Curr. Opin. Hematol. 17, 9-17.
123. Wynn R.F., Hart C.A., Corradi-Perini C., O'Neill L., Evans C.A., Wraith J.E., Fairbairn L.J. and Bellantuono I. (2004). A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104, 2643-2645.
124. Xiao Q., Wang S.K., Tian H., Xin L., Zou Z.G., Hu Y.L., Chang C.M., Wang X.Y., Yin Q.S., Zhang X.H. and Wang L.Y. (2012). TNF-alpha increases bone marrow mesenchymal stem cell migration to ischemic tissues. Cell Biochem. Biophys. 62, 409-414.
125. Xu F., Shi J., Yu B., Ni W., Wu X. and Gu Z. (2010). Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol. Rep. 23, 1561-1567.
126. Xu S., Menu E., De Becker A., Van Camp, B., Vanderkerken K. and Van Riet I. (2012). Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 30, 266-279.
127. Yu J., Li M., Qu Z., Yan D., Li D. and Ruan Q. (2010). SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal cells toward areas of heart myocardial infarction through activation of PI3K/Akt. J. Cardiovasc. Pharmacol. 55, 496-505.
128. Zhang A., Wang Y., Ye Z., Xie H., Zhou L. and Zheng S. (2010). Mechanism of TNF-alpha-induced migration and hepatocyte growth factor production in human mesenchymal stem cells. J. Cell Biochem. 111, 469-475.
129. Zielske S.P., Livant D.L. and Lawrence T.S. (2009). Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int. J. Radiat. Oncol. Biol. Phys. 75, 843-853.